Dual Light Therapy Device for Dry Eye and OSD Management - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dual Light Therapy Device for Dry Eye and OSD Management

Essilor Instruments' eye-light® delivers targeted, condition-specific management for ocular surface diseases

  • June 2, 2026

  • 2 min

Share

Objective:

To introduce the eye-light® device for managing ocular surface diseases (OSD) and dry eye.

Key Findings:
  • Eye-light® has shown greater improvements in tear film quality and patient symptoms compared to IPL-only solutions.
  • The combination of light therapies is recognized in the TFOS DEWS III Management & Therapy Report as effective for managing OSD.
  • Clinical studies indicate superior efficacy of the combined therapies over long-term eye-drop therapy, improving tear stability and clinical outcomes.
  • Research shows long-lasting results maintained for up to 18 months.
Interpretation:

The all-in-one approach to light therapy aims to address the root causes of ocular surface diseases, enhancing patient management and experience.

Limitations:
Conclusion:

The introduction of eye-light® may lead to meaningful improvements in the quality of life for patients with dry eye disease.

Original Source(s)

Dual Light Therapy Device for Dry Eye and OSD Management

  • June 2, 2026

Related Content

Dry Eye Dx and Tx: <br>Telehealth Enters the Dry Eye Arena</br>

Reflections on Lumenis Accelerate from Laura Periman, MD

Optometric Management caught up with Laura Periman, MD, at the Lumenis Accelerate Owner’s Summit in Chicago on August 28 to discuss what attendees could take away from the event, both in clinical pearls and workflows and in practice management lessons.

  • September 1, 2026

  • 4 min
Between the Snapshots: The Case for Continuous Engagement

Taking care of eye patients between visits